CN106617077A - Fish oil microcapsule for reducing blood lipid and preparation method thereof - Google Patents
Fish oil microcapsule for reducing blood lipid and preparation method thereof Download PDFInfo
- Publication number
- CN106617077A CN106617077A CN201611008012.4A CN201611008012A CN106617077A CN 106617077 A CN106617077 A CN 106617077A CN 201611008012 A CN201611008012 A CN 201611008012A CN 106617077 A CN106617077 A CN 106617077A
- Authority
- CN
- China
- Prior art keywords
- fish oil
- capsule
- blood lipid
- reducing blood
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000021323 fish oil Nutrition 0.000 title claims abstract description 75
- 239000003094 microcapsule Substances 0.000 title claims abstract description 38
- 239000008280 blood Substances 0.000 title claims abstract description 28
- 210000004369 blood Anatomy 0.000 title claims abstract description 28
- 230000001603 reducing effect Effects 0.000 title claims abstract description 22
- 150000002632 lipids Chemical class 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 235000019198 oils Nutrition 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims description 16
- 241000251778 Squalus acanthias Species 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 239000003643 water by type Substances 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 16
- 239000003921 oil Substances 0.000 abstract description 9
- 229930003427 Vitamin E Natural products 0.000 abstract description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 8
- 239000011709 vitamin E Substances 0.000 abstract description 8
- 235000019165 vitamin E Nutrition 0.000 abstract description 8
- 229940046009 vitamin E Drugs 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- 239000001301 oxygen Substances 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 230000006866 deterioration Effects 0.000 abstract description 2
- 235000013373 food additive Nutrition 0.000 abstract description 2
- 239000002778 food additive Substances 0.000 abstract description 2
- 238000005286 illumination Methods 0.000 abstract description 2
- 230000001590 oxidative effect Effects 0.000 abstract description 2
- 150000002978 peroxides Chemical class 0.000 abstract description 2
- 241001635206 Conger conger Species 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000010686 shark liver oil Substances 0.000 abstract 1
- 229940069764 shark liver oil Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 10
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 9
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 9
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 9
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 9
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000005253 cladding Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a fish oil microcapsule for reducing blood lipid and a preparation method thereof, belonging to the technical field of health care products. The fish oil microcapsule contains the following ingredients in parts by weight: 60-90 parts of sea eel oil, 5-25 parts of shark liver oil and 0.1-8 parts of vitamin E. The fish oil microcapsule has an excellent blood lipid reducing effect, can be used for improving the immunity of a human body and clearing the metabolic peroxide in the body, and can be easily absorbed by the human body; the fish oil is wrapped by adopting a microcapsule wrapping technology, the fish oil holding rate achieves 86% or above, furthermore, the oxidative deterioration of the fish oil caused by oxygen, illumination and the like can be prevented, fishlike smell can be covered, and the food can be processed and stored conveniently, so that the fish oil microcapsule can be taken as a food additive to be added into different foods, and the additional value can be increased.
Description
Technical field
The invention belongs to health product technology field, more particularly to a kind of fish oil micro-capsule of reducing blood lipid and preparation method thereof.
Background technology
Aliphatic acid is one of nutriment needed by human.PUFAs (unrighted acid) mainly includes w-3 and w-6 two
Individual series, but w-3 unrighted acids (w-3PUFAs) can not synthesize by human body, mainly be supplied by marine organisms.W-3 is unsaturated
Aliphatic acid (w-3PUFAs) belongs to long-chain unsaturated fatty acid, mainly including EPA (eicosapentaenoic acid) and DHA (22 carbon
Acid).At present, medical discovery w-3PUFAs has extensive and important biological function, mainly includes stabilizing cell membrane work(
Can, controlling gene expression, maintain cell factor and lipoprotein balance, its angiocardiopathy, reduce tumour, exploitation infant intelligence
With anti-ageing aspect of waiting for a long time.Fish oil is rich in EPA and DHA, is one of common health products of existing market.Wherein, in eel fish oil also
Rich in AKGs (AKGs), with following two big effects：1. stimulate the generation of immunocyte, improve leucocyte, lymph thin
Born of the same parents and hematoblastic quantity, and promote activated immune cell, strengthen the immunologic function of body；2. AKGs is a kind of antioxygen of strength
Agent, has unique effects to the free radical in scavenger-cell.
W-3PUFAs can reduce the generation and removing of plasma triglyceride, reduce Low-density lipoprotein and extremely low close
Degree lipoprotein cholesterol, increasing high density lipoprotein cholesterol.Wherein, that play Main Function is EPA and DHA.EPA、DHA
(docosapentanoic acid and docosahexenoic acid) combines vitamin E energy effective protection and strengthens original prostacyclin T and thromboxane A
The function of balance, and by strengthen HDL (HDL) tolerance against oxidative and protection blood vessel endothelium rely on diastole because
Sub (DERP), obtains and adjusts blood fat, and reducing blood viscosity improves blood circulation.Strengthen oxidation resistance, make body from super
Oxidation material is injured, and removes human free radical, strengthens human body oxygen-resistant ability.Wherein EPA is with more reduction blood viscosity, neutralizing blood
The fat that inside pipe wall is more than, reduces triglycerin and cholesterol (LDL) concentration, reaches cleaning thrombus, reduction blood fat, prevention and improvement
The effect of cardiovascular and cerebrovascular disease, by internationally recognized " blood vessel scavenger ".Because EPA, DHA contain multiple double bonds, thus to oxygen,
Light and heat is extremely sensitive, easily aoxidizes.EPA and DHA, not only to healthy unhelpful, is caused greatly on the contrary once aoxidizing to human body
Injury.
Application No. 201310116505.X, entitled " a kind of fish oil soft capsule and preparation method thereof " patent of invention, it is public
A kind of fish oil soft capsule and preparation method thereof is opened, its primary raw material includes deep sea fish oil and vitamin E, wherein, deep sea fish oil
It is 80-100 with the weight ratio of vitamin E:0.1-10, by preparing content, making utricule, prepare the steps such as capsule and obtain fish
Fat capsule.Soft capsule cladding liquid fish oil inconvenience flowing with mix, inconvenient food processing and preservation.
Application No. 201110240888.2, a kind of entitled " inclusion method for fish oil " patent of invention, disclose a kind of fish
Oily inclusion method, it is fully emulsified by fish oil initially with Tween 80 emulsifying agent, forms finely dispersed small emulsion droplet, then uses
Beta-schardinger dextrin is tentatively included to fish oil, forms fish oil-beta cyclodextrin clathrate；Secondly, by Sodium Caseinate and microcrystalline cellulose
The inclusion agents such as element re-form the protein-fibre element sealing coated layer of thin film shape to fish oil-beta cyclodextrin clathrate surface.
Using secondary cladding, complex process, the prices of raw materials are expensive, manufacture high cost, and practicality is not strong.
The content of the invention
The technological deficiency of fish oil antioxidation difference in order to overcome prior art, the present invention provides a kind of with reducing blood lipid work
Fish oil micro-capsule and preparation method thereof.
The purpose of the present invention is achieved through the following technical solutions：A kind of fish oil micro-capsule of reducing blood lipid, by as follows by weight
Number meter into being grouped into：60-90 part eel fish oil, 5-25 parts dogfish oil and 0.1-8 part vitamin Es.
EPA content is not less than 20% in the fish oil micro-capsule of the reducing blood lipid, and DHA content is not less than 13%, AKGs contents
It is not less than 5%.
The core of the fish oil micro-capsule of the reducing blood lipid is adopted and prepared with the following method：By 60-90 part eel fish oil and 5-25
Part dogfish oil mixes 30-60min, is subsequently adding 0.1-8 part vitamin Es, mixes 15-30min, obtains core.
The preparation method of the fish oil micro-capsule of the reducing blood lipid, comprises the steps：
(1) 80 portions of purified waters, 3 parts of gelatin and 17 portions of sucrose are added under 55～75 DEG C, 8000r/min, are stirred 30 minutes,
Cooling, obtains suspension；
(2) by the core add step (1) suspension in, be heated to 55～75 DEG C, in 13500r/min stir 2～
3 hours, obtain fish oil inclusion liquid；
(3) by the fish oil of step (2) inclusion liquid by high pressure homogenizer 3 times, pressure is 40MPa；
(4) the fish oil inclusion liquid after step (3) homogeneous is spray-dried, EAT is 155 DEG C, and leaving air temp is 75
DEG C, obtain fish oil micro-capsule.
The invention has the advantages that：The present invention has excellent effect for reducing blood fat, increases body immunity, removes
The peroxide of metabolism in vivo, and be easily absorbed by the body；And cladded in fish oil using microcapsules cladding technology, fish oil is held
Have rate up to more than 86%, and can prevent oxygen, illumination etc. from causing fish oil oxidation deterioration, cover fishlike smell, be easy to food processing and
Preserve so as to can be added in different food products as food additives, increase its added value.
Specific embodiment
With reference to embodiment, the present invention is described in further detail, but embodiments of the present invention not limited to this.
Embodiment 1
A kind of fish oil micro-capsule of reducing blood lipid, its core includes 85 parts of weight of eel fish oil, 14 parts of weight of dogfish oil, dimension
Raw element 1 part of weight of E.
The preparation method of the fish oil micro-capsule core includes：Stir than eel fish oil and dogfish oil mixing by formulation weight
Mix 60 minutes, add vitamin E, mix 30 minutes, obtain core.
The fish oil micro-capsule inclusion method includes that concrete grammar is as follows：
(1) purified water, gelatin and sucrose are added under 65 DEG C, the stir speed (S.S.) of 8000r/min, is stirred 30 minutes, cooling,
Obtain suspension；
(2) the microcapsules core for having prepared is added in the suspension of above-mentioned preparation, 65 DEG C is heated to, using 13500r/
Min high-speed stirreds 3 hours, are obtained fish oil inclusion liquid；
(3) by fish oil inclusion liquid by high pressure homogenizer 3 times, pressure is 40MPa；
(4) the fish oil inclusion liquid after homogeneous is spray-dried, EAT is 155 DEG C, and leaving air temp is 75 DEG C, obtains fish
Oil microcapsule.
Embodiment 2
A kind of fish oil micro-capsule of reducing blood lipid, its core include 90 parts of weight of eel fish oil, 9.5 parts of weight of dogfish oil,
0.5 part of weight of vitamin E.
The preparation method of the fish oil micro-capsule core includes：Stir than eel fish oil and dogfish oil mixing by formulation weight
Mix 60 minutes, add vitamin E, mix 30 minutes, obtain core.
The fish oil micro-capsule inclusion method includes that concrete grammar is as follows：
(1) purified water, gelatin and sucrose are added under 70 DEG C, the stir speed (S.S.) of 8000r/min, is stirred 30 minutes, cooling,
Obtain suspension；
(2) the microcapsules core for having prepared is added in the suspension of above-mentioned preparation, 70 DEG C is heated to, using 13500r/
Min high-speed stirreds 3 hours, are obtained fish oil inclusion liquid；
(3) by fish oil inclusion liquid by high pressure homogenizer 3 times, pressure is 40MPa；
(4) the fish oil inclusion liquid after homogeneous is spray-dried, EAT is 155 DEG C, and leaving air temp is 75 DEG C, obtains fish
Oil microcapsule.
Embodiment 3
A kind of fish oil micro-capsule of reducing blood lipid, its core includes 80 parts of weight of eel fish oil, 15 parts of weight of dogfish oil, dimension
Raw element 5 parts of weight of E.
The preparation method of the fish oil micro-capsule core includes：Stir than eel fish oil and dogfish oil mixing by formulation weight
Mix 60 minutes, add vitamin E, mix 30 minutes, obtain core.
The fish oil micro-capsule inclusion method includes that concrete grammar is as follows：
(1) purified water, gelatin and sucrose are added under 65 DEG C, the stir speed (S.S.) of 8000r/min, is stirred 30 minutes, cooling,
Obtain suspension；
(2) the microcapsules core for having prepared is added in the suspension of above-mentioned preparation, 70 DEG C is heated to, using 13500r/
Min high-speed stirreds 3 hours, are obtained fish oil inclusion liquid；
(3) by fish oil inclusion liquid by high pressure homogenizer 3 times, pressure is 40MPa；
(4) the fish oil inclusion liquid after homogeneous is spray-dried, EAT is 155 DEG C, and leaving air temp is 75 DEG C, obtains fish
Oil microcapsule.
By regulation, cholesterol (TC) is more than 6.5mmol/L (250mg/dl) or triglycerides (TG) more than 1.65mmol/L
(150mg/dl) person is classified as hyperlipemia.100 hyperlipemic patients derive from Nanfang Hospital, wherein man 64 and female 36, year
Age at 31～65 years old, average 52 years old.Wherein simple hyperlipemia 53, merges coronary heart disease or hyperpietic 27, overweight people
18.The oral 20g of patient per, 3 times a day, continuously takes 30 days.Take before and after Blood Lipid and be relatively shown in Table 1, reduce TC, TG
Bloodlipid-lowering conspicuousness be shown in Table 2, take before and after immune indexes and be shown in Table 3.More than Jing clinical trial results can be seen that the present invention
Fish oil micro-capsule can significant effect for reducing blood fat, body immunity can be effectively improved.
Table 1 takes before and after Blood Lipid comparative result
The Bloodlipid-lowering significant result of table 2
Table 3 takes before and after immunity Indexes Comparison result
Above-described embodiment is the present invention preferably embodiment, but embodiments of the present invention not by above-described embodiment
Limit, other any Spirit Essences without departing from the present invention and the change, modification, replacement made under principle, combine, simplification,
Equivalent substitute mode is should be, is included within protection scope of the present invention.
Claims (4)
1. a kind of fish oil micro-capsule of reducing blood lipid, it is characterised in that by counting by weight as follows into being grouped into：60-90 parts
Eel fish oil, 5-25 parts dogfish oil and 0.1-8 part vitamin Es.
2. the fish oil micro-capsule of reducing blood lipid according to claim 1, it is characterised in that the fish oil micro-capsule of the reducing blood lipid
Middle EPA content is not less than 20%, and DHA content is not less than 13%, AKGs contents and is not less than 5%.
3. the fish oil micro-capsule of reducing blood lipid according to claim 1, it is characterised in that the fish oil micro-capsule of the reducing blood lipid
Core adopt and prepare with the following method：60-90 part eel fish oil and 5-25 parts dogfish oil are mixed into 30-60min, then
0.1-8 part vitamin Es are added, 15-30min is mixed, core is obtained.
4. the preparation method of the fish oil micro-capsule of reducing blood lipid described in claim 1, it is characterised in that comprise the steps：
(1) 80 portions of purified waters, 3 parts of gelatin and 17 portions of sucrose are added under 55～75 DEG C, 8000r/min, is stirred 30 minutes, it is cold
But, suspension is obtained；
(2) during the core to be added the suspension of step (1), 55～75 DEG C are heated to, it is little in 13500r/min stirrings 2～3
When, obtain fish oil inclusion liquid；
(3) by the fish oil of step (2) inclusion liquid by high pressure homogenizer 3 times, pressure is 40MPa；
(4) the fish oil inclusion liquid after step (3) homogeneous is spray-dried, EAT is 155 DEG C, and leaving air temp is 75 DEG C, is obtained
To fish oil micro-capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611008012.4A CN106617077A (en) | 2016-11-16 | 2016-11-16 | Fish oil microcapsule for reducing blood lipid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611008012.4A CN106617077A (en) | 2016-11-16 | 2016-11-16 | Fish oil microcapsule for reducing blood lipid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106617077A true CN106617077A (en) | 2017-05-10 |
Family
ID=58805385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611008012.4A Pending CN106617077A (en) | 2016-11-16 | 2016-11-16 | Fish oil microcapsule for reducing blood lipid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106617077A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108175102A (en) * | 2017-11-28 | 2018-06-19 | 芜湖市诺康生物科技有限公司 | A kind of preparation method of cod liver oil soft capsule |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1345588A (en) * | 2000-09-29 | 2002-04-24 | 国家海洋药物工程技术研究中心 | No-stinking fish-oil composite micro-capsule and preparation process |
| CN101669920A (en) * | 2008-09-10 | 2010-03-17 | 阜宁怀仁生物有限公司 | Strong anti-oxidation DHA microcapsule and preparation method thereof |
-
2016
- 2016-11-16 CN CN201611008012.4A patent/CN106617077A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1345588A (en) * | 2000-09-29 | 2002-04-24 | 国家海洋药物工程技术研究中心 | No-stinking fish-oil composite micro-capsule and preparation process |
| CN101669920A (en) * | 2008-09-10 | 2010-03-17 | 阜宁怀仁生物有限公司 | Strong anti-oxidation DHA microcapsule and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 中一贝等: "《食物营养与健康 7 山珍篇》", 31 December 2001, 中国物资出版社 * |
| 无锡轻工大学等: "《21世纪的食品 食品与资源、技术、环境 1》", 31 October 2000, 中国轻工业出版社 * |
| 黄小芬等: "鳗鱼油微胶囊化工艺条件的研究", 《食品工业》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108175102A (en) * | 2017-11-28 | 2018-06-19 | 芜湖市诺康生物科技有限公司 | A kind of preparation method of cod liver oil soft capsule |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104432059B (en) | A kind of anti-acid microalgae DHA grease microscapsule powder | |
| JP2019047817A (en) | Beverage composition for weight gain suppression, and method for weight gain suppression | |
| CN108720021A (en) | DHA algal oil microscapsule powder and preparation method thereof | |
| CN105476959B (en) | A kind of medium chain triglycerides nano-emulsion and preparation method thereof | |
| CN105613789A (en) | High-fat and high-dietary-fiber composite animal and plant powdered oil and preparation method and application thereof | |
| CN104522649B (en) | A kind of DHA algal oil soft capsule containing Oleum Perillae and preparation method thereof | |
| CN103190619A (en) | Fish oil and linseed oil soft capsules and preparation method thereof | |
| CN101843336A (en) | Linseed oil fat emulsion oral solution, beverage and manufacturing method thereof | |
| CN107660620A (en) | A kind of sheep base oil grease microcapsule powder and preparation method thereof | |
| CN101816423A (en) | Purple perilla seed oil lipid emulsion oral solution, beverage and manufacturing method thereof | |
| CN106720333A (en) | Acidified milk containing DHA and EPA and preparation method thereof | |
| CN106617077A (en) | Fish oil microcapsule for reducing blood lipid and preparation method thereof | |
| CN105726478A (en) | Oral EPA(Eicoeapentaenoic acid) O/W type nanoemulsion and preparation method thereof | |
| CN101167793A (en) | Walnut oil fat emulsion and manufacturing method thereof | |
| CN104127857A (en) | Fish oil soft capsule and preparation method thereof | |
| CN104323282A (en) | Soft capsule with chia seed oil and preparation method thereof | |
| CN111743996A (en) | Oral emulsion for improving memory and senile dementia and preparation method thereof | |
| CN103651968B (en) | A kind of giant salamander purple perilla ready-mixed oil and preparation method thereof | |
| CN101869297A (en) | Compound evening primrose and perilla herb oil fat emulsion oral solution, beverage and preparation method | |
| Lee | Essent ial Fat ty Acids | |
| CN1537459A (en) | Lecithinum emulsified soy sauce, and its prepn. method | |
| CN114158732A (en) | Polyunsaturated fatty acid triglyceride microcapsule powder and preparation method thereof | |
| CN101869298A (en) | Compound walnut and linseed oil fat emulsion oral solution, beverage and preparation method | |
| CN110050847A (en) | A kind of high fat diet and fatty acid mixed edible plant blend oil | |
| CN101978950A (en) | Alpha-linolenic acid ester fat emulsion injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |